

1      Source tracking and global distribution of the mobilized tigecycline resistant gene *tet*(X)  
2      Rong-min Zhang<sup>1,2,3†</sup>, Jian Sun<sup>1,2,3†</sup>, Ruan-yang Sun<sup>1,2,3</sup>, Min-ge Wang<sup>1,2,3</sup>, Chao-yue Cui<sup>1,2,3</sup>,  
3      Liang-xing Fang<sup>1,2,3</sup>, Mei-na Liao<sup>1,2,3</sup>, Xiao-qing Lu<sup>1,2,3</sup>, Yong-xin Liu<sup>4</sup>, Xiao-Ping Liao<sup>1,2,3\*</sup>,  
4      Ya-Hong Liu<sup>1,2,3\*</sup>

5

6      <sup>1</sup>National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria,  
7      South China Agricultural University, Guangzhou 510642, China.

8      <sup>2</sup>Laboratory of Veterinary Pharmacology, College of Veterinary Medicine, South China  
9      Agricultural University, Guangzhou 510642, China.

10     <sup>3</sup>Guangdong Laboratory for Lingnan Modern Agriculture, Guangzhou, P. R. China

11     <sup>4</sup>State Key Laboratory of Plant Genomics, Institute of Genetics and Developmental Biology,  
12     Innovation Academy for Seed Design, Chinese Academy of Sciences, Beijing, China.

13

14     National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria,  
15     South China Agricultural University, Guangzhou 510642, China.

16     <sup>†</sup>These two authors contributed equally to this work.

17

18     \*Address correspondence to Xiaoping-Liao and Yahong-Liu, E-mail: [xpliao@scau.edu.cn](mailto:xpliao@scau.edu.cn) and  
19     [lyh@scau.edu.cn](mailto:lyh@scau.edu.cn)

20     Corresponding author at: College of Veterinary Medicine, South China Agricultural University,  
21     Guangzhou, Guangdong province, PR China.

22

23

24

25 **Abstract**

26 The emergence of *tet(X)* genes has compromised the clinical use of the last-line antibiotic  
27 tigecycline. We identified 322 (1.21%) *tet(X)* positive samples from 12,829 human microbiome  
28 samples distributed in four continents (Asia, Europe, North America and South America) using  
29 retrospective data from worldwide. These *tet(X)* genes were dominated by *tet(X2)*-like orthologs  
30 but we also identified 12 samples carrying novel *tet(X)* genes, designed *tet(X15)* and *tet(X16)*,  
31 that were resistant to tigecycline. The metagenomic analysis revealed these *tet(X)* genes  
32 distributed in anaerobes dominated by *Bacteroidaceae* (78.89%) of human-gut origin. The  
33 transmission of these *tet(X2)*-like orthologs between *Bacteroidaceae* and *Riemerella anatipestifer*  
34 was primarily promoted by the mobile elements *ISBf11* and *IS4351*. *tet(X2)*-like orthologs was  
35 also developed during transmission by mutation to high-level tigecycline resistant determinants  
36 *tet(X15)* and *tet(X16)*. Further tracing these *tet(X)* in single bacterial isolate from public  
37 repository indicated that *tet(X)* genes were present as early as 1960s in *R. anatipestifer* that was  
38 the primary *tet(X)* carrier at early stage (before 2000). The *tet(X2)* and non-*tet(X2)* orthologs were  
39 primarily distributed in humans and food animals respectively, and non-*tet(X2)* were dominated  
40 by *tet(X3)* and *tet(X4)*. Genomic comparison indicated these *tet(X)* genes were likely to be  
41 generated during *tet(X)* transmission between *Flavobacteriaceae* and *E. coli/Acinetobacter* spp.,  
42 and *ISCR2* played a key role in the transmission. These results suggest *R. anatipestifer* was the  
43 potential ancestral source of *tet(X)* gene. Additionally, *Bacteroidaceae* of human-gut origin was an  
44 important hidden reservoir and mutational incubator for the mobile *tet(X)* genes that enabled  
45 spread to facultative anaerobes and aerobes.

46 Keywords: Tigecycline resistance, *Tet(X)*, Source tracking, Human microbiome, *Riemerella*

47 *anatipesi*, *Bacteroidaceae*

48 **Introduction**

49 The first generation of tetracycline antibiotics consisted of tetracycline, chlortetracycline and  
50 oxytetracycline and were put into clinical practice in 1952 (1) while the second generation  
51 derivatives doxycycline and minocycline were put into use in 1976 (2). These antibiotics have  
52 been incorporated into animal feed to improve growth and feed efficiency (3). However, bacterial  
53 resistance to the tetracyclines was observed from the very beginning of their usage. To date, more  
54 than 65 specific resistant determinants and 9 MDR efflux pump genes of the root  
55 nodulation-division (RND) superfamily have been confirmed including AdeABC, AcrAB-TolC  
56 and MexAB-OprM (2). These determinants confer resistance to first and second generation  
57 tetracyclines and are widely distributed among 130 Gram-negative and Gram-positive bacteria (2).

58 A third-generation tetracycline (tigecycline) was approved in the United States in 2005 and  
59 its use in the EU and China was authorized in 2006 and 2010, respectively (4, 5). Tigecycline has  
60 a robust treatment range and includes bacteria resistant to first and second generation tetracyclines  
61 (6), and is a 'last resort' antibiotic used to treat severe infections caused by carbapenem- and  
62 colistin-resistant pathogens (5). Thus, this antibiotic was classified as a critically important  
63 antimicrobial by the World Health Organization and its usage is restricted (7). However as early as  
64 1884, the transferable gene *tet*(X) displaying tigecycline insusceptibility was discovered on an R  
65 plasmid from a *B. fragilis* isolate of human origin. This was the earliest occurrence of an antibiotic  
66 resistance gene (ARG) that directly inactivated tetracyclines (8). The *tet*(X) gene was only  
67 functional under aerobic growth conditions because it is a flavin dependent monooxygenase that  
68 requires FAD, NADPH, Mg<sup>2+</sup> and O<sub>2</sub> to inactive almost all of the tetracycline class (9). In 2001

69 the existence of *tet*(X1) and *tet*(X2) were confirmed on a transposon from *Bacteroides*  
70 *thetaiotaomicron* of human origin and shared 61.7 and 99.5 % amino acid identity with *tet*(X),  
71 respectively. To date, *tet*(X)/*tet*(X2) genes have already spread to 16 countries/regions covering  
72 five continents (Asia, Europe, North America, South America and Africa) (2). A small comfort  
73 was that these ARGs displayed low level tigecycline resistance (MIC  $\leq$  2ug.ml<sup>-1</sup>) (2).

74 The emergence of plasmid-mediated high-level tigecycline resistance encoded by the *tet*(X3)  
75 and *tet*(X4) genes in 2019 posed a severe threat to public health (7, 10). Additionally, 10 more  
76 *tet*(X) orthologs have been identified and include *tet*(X5) - *tet*(X14)) (11-14). These orthologs  
77 were primarily found in food animals especially swine, including *tet*(X3), *tet*(X4), *tet*(X6) and  
78 *tet*(X14) firstly detected in *Acinetobacter baumanii*, *Escherichia coli*, *Myroides phaeus* and  
79 *Empedobacter stercoris*, respectively. The *tet*(3.2) and *tet*(X5) gene were identified from an  
80 *Empedobacter brevis* isolate of shrimp origin and a *Acinetobacter baumannii* isolate of human origin,  
81 respectively. All the *tet*(X7) - *tet*(X13) orthologs were identified directly from gut-derived  
82 metagenomic libraries, but their host bacteria were unknown. Epidemiological studies (2, 15, 16)  
83 indicated the dissemination of these *tet*(X) orthologs were dominated by *tet*(X3) and *tet*(X4) that were  
84 primarily detected from *Acinetobacter* spp. and *E. coli*, respectively. Furthermore, *tet*(X3)/*tet*(X4)  
85 samples from humans, animals and meat for consumption revealed a prevalence of 0.3 - 66.7 % and the  
86 highest level of 66.7 % was detected from pig caecum samples from abattoirs (7). Compared with the  
87 *tet*(X3)/*tet*(X4) in animal isolates (6.9%, 73/1060) (7), lower prevalence from human (0.32%, 4/1250)  
88 were observed in a retrospective screening of *tet*(X)-carrying clinical isolates (5).

89 The *tet*(X) genes have been primarily identified using traditional cultural methods and this  
90 imposed limitations on their identification including the loss of uncultured bacteria, low-throughput

91 and long processing times. Although the *tet*(X7) - *tet*(X13) orthologs were found directly from  
92 gut-associated samples using metagenomic sequencing, the bacterial hosts, relative abundance and  
93 propagative characteristics were absent (14). Nonetheless, public repositories are a promising  
94 high-throughput resource for exploring antibiotic resistomes. For instance, a retrospective  
95 epidemiological study based on the available public bacterial gene datasets revealed that the food chain  
96 was a potential dissemination pathway for *mcr-1* (17). Additionally, a metagenomic screening study  
97 based on public metagenome datasets revealed a high detection rate of *tet*(X3) (25.4 %) in poultry  
98 samples (18). However, there are few studies that utilize data mining for *tet*(X) in public databases (18,  
99 19). In addition, public data repositories including GenBank are a valuable resource for the exploration  
100 of novel bacterial species. For instance, a recent study utilized 9,428 metagenomes to reconstruct  
101 154,723 microbial genome bins that generated 4,390 species level genome bins (SGB) including  
102 77 % of which were not present in public repositories (20). Identification of *tet*(X) genes from  
103 these SGBs and tracing their distribution in assembly isolates from public repository may provide  
104 a new perspective for source tracking of the global spread of *tet*(X).

105 In the current study, we utilized these data mining techniques and discovered that *tet*(X) had  
106 emerged as early as 1960 and the *Riemerella anatipesfifer* was its potential ancestral source.  
107 Additionally, *Bacteroidaceae* of human gut origin were a hidden reservoir and mutational  
108 incubator for mobile *tet*(X) genes that enabled spread to facultative anaerobes and aerobes.

## 109 **Methods**

### 110 **Collection of microbial genomic sequences from human microbiome in retrospective data**

111 A total of 26,728 metagenomic samples of human-microbiome origin deposited in public  
112 repositories were downloaded and reconstructed microbial genomic bins (MGBs) to explore new

113 bacterial species in previous studies (20-22). We removed the duplicative samples from these  
114 metagenomic samples according their accession number and found a total of 12,829 non-duplicate  
115 metagenomic samples from 31 countries. These samples were reconstructed into 202,265 MGBs  
116 in previous studies (20-22) (Table S1 and S2) and the online released data were screened for the  
117 presence of all known *tet*(X) orthologs using BLAST using an 80 % identity and 70 % hit length  
118 cut-off in current study. The prevalence of *tet*(X) in 31 countries were plotted using R version  
119 3.5.3. Phylogenetic analysis for amino acid sequences of all *Tet*(X) gene products was constructed  
120 using neighbor joining with the default parameters in Mega X Version 10.0.5 (23) and alignments  
121 were constructed using ESPript 3 (24).

122 **Functional identification of *Tet*(X)s**

123 Tigecycline resistance for these gene products was assessed by synthesis of full-length  
124 nucleotide sequences of all detected *tet*(X) genes. *EcoRI* and a *SalI* sites were then added 5' and 3'  
125 respectively (Tsingke Biological Technology, Beijing, China). The synthesized *tet*(X) genes were  
126 cloned into plasmid vector pBAD24 and transformed into competent *E. coli* JM109 as described  
127 in our previous study (25). The transconjugants *E. coli* JM109+pBAD24-*tet*(X4) and *E. coli*  
128 JM109+pBAD24, were used as positive and negative controls, respectively, as previously  
129 described (25). The minimum inhibitory concentration (MIC) for tetracycline, doxycycline,  
130 minocycline, tigecycline, eravacycline and omadacycline were determined by the broth  
131 microdilution method in accordance with Clinical and Laboratory Standards Institute (CLSI)  
132 guidelines. Tetracycline, doxycycline and minocycline breakpoints were interpreted according to  
133 the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines  
134 ([http://www.eucast.org/clinical\\_breakpoints](http://www.eucast.org/clinical_breakpoints)). The United States FDA criteria was employed to

135 interpret tigecycline breakpoints for *E. coli* and MIC  $\geq 4$  mg L<sup>-1</sup> was considered non-susceptible  
136 while eravacycline and omadacycline were uninterpreted with no breakpoint. *E. coli* ATCC 25922  
137 was used as the quality control strain.

138 **Taxonomic assignment and phylogenetic analysis of *tet(X)*s-carrying MGBs**

139 We obtained 322 *tet(X)*-carrying MGBs from three previous studies (20-22). This group  
140 included taxonomic assignments for 196 that had been previously annotated (20) while the  
141 remaining 126 were annotated using metaWRAP-Annotate-bins module using the MetaWRAP  
142 pipeline and default parameters (26). Briefly, the assembly contigs from each *tet(X)*-carrying  
143 MGB was taxonomically profiled using Kraken2 (27) and then this entire metagenomic bin could  
144 conservatively and accurately estimate the taxonomic profiles (26).

145 The phylogenetic structure for the *tet(X)*-carrying MGBs were performed using an automatic  
146 PhyloPhlAn (3.0) pipeline (20, 28), through which the phylogeny in Figure 1b was built using 400  
147 universal PhyloPhlAn markers with parameter: “--diversity high --accurate --min\_num\_markers  
148 80.” This pipeline integrates diamond (version 0.9.32) , mafft (version 7.464) (29), trimal (version  
149 1.4.rev15) (30) and RAxML (version 8.2.12) (31), and the parameters of these software were set  
150 as described previously (20). The phylogenetic tress in Figure 1b were plotted using GraPhlan  
151 (version 1.1.3) (32).

152 **Phylogenetic analyses of the *tet(X)* carrying isolates and evolutionary timescale for the**  
153 ***tet(X)*s from isolates**

154 To further trace the spread of all *tet(X)*s in culturable bacteria isolates, a total of 774,435  
155 bacteria assembled whole genome sequences (WGS) were downloaded from the NCBI database as  
156 of November 7<sup>th</sup>, 2020. *tet(X)*-like OFRs were determined using BLATX against all the *tet(X)*s

157 variants mentioned in current study with a minimum similarity of 70% and 100% coverage. The  
158 collection date, origin, countries and the bacterial host of the *tet(X)*-positive isolates were  
159 retrieved according to their Biosample Number. The phylogenetic structure for the *tet(X)*-carrying  
160 isolates were also performed using PhyloPhlAn (3.0) pipeline mentioned above.

161 To determine the evolutionary history of *tet(X)*s, the earliest emergence of *tet(X)* variants  
162 (with collection date) with a 388 amino acid (aa) length were applied to generate a chronogram  
163 using Bayesian evolutionary analysis version 1.10 (33). For all model combinations, three  
164 independent chains of 100 million generations each were run to ensure convergence with sampling  
165 every 1,000 iterations. Tracer v1.7.1 was used to assess convergence using all parameter effective  
166 sampling sizes of > 200 (34). LogCombiner v2.6.1 was used to combine tree files and a maximum  
167 clade credibility tree was created using TreeAnnotator v2.6.0 (34). Tree annotation was visualized  
168 using iTOL (35) and FigTree version 1.4.2.

169 **Annotation and comparison of the genomic region flanking the *tet(X)* gene**

170 The *tet(X)*-carrying contig were extracted from the MGBs of metagenomic analysis and  
171 isolates from public repository. CD-HIT was employed to group *tet(X)*-carrying full length contigs  
172 using a cutoff with a minimum similarity of 97 % over 97 % of the query coverage (36). These  
173 *tet(X)*-carrying contigs were annotated using Prokka (37) and in conjunction with standalone  
174 BLAST analyses against the ResFinder (38) and ISfinder (39) databases to cross-validate ARGs  
175 and mobile genetic elements, respectively.

176 **Results**

177 **Identification of Tet(X) orthologs**

178 We accessed a total of 202,265 MGBs constructed from 12,829 metagenomic samples of

179 human-microbiome origin and found 322 (1.21 %) of them encoded 388 aa proteins with 96.13 -  
180 100% similarity with Tet(X) orthologs reported in a previous study (11) (Table S2). In particular,  
181 96.27 % (310/322) of them shared 98.71 - 100 % identity with Tet(X2) (Acc. No. AJ311171) and  
182 phylogenetically could be grouped into 15 *tet*(X2)-like clades (Figure S1 and S2, Table S3). The  
183 remaining 3.73 % (12/322) shared < 98.20 % identical with the known Tet(X). Since there was not  
184 a criterion for assignment of Tet(X) orthologs in previous studies (11, 14), we temporarily  
185 designated these *tet*(X2)-like orthologs as *tet*(X2.2) to *tet*(X2.16). These orthologs represented a  
186 large proportion of samples (n=12,829) from 19 countries and were therefore likely represented a  
187 relatively comprehensive assessment of *tet*(X2)-like orthologs. We therefore tentatively used the  
188 lowest cutoff of 98.20 % between *tet*(X2)-like orthologs (*tet*(X2.15) vs *tet*(X2.16)) for assignment  
189 of novel *tet*(X) orthologs. Based on this, we found two new *tet*(X) orthologs and their subtypes  
190 shared less than 98.20% amino acid identity with their closest neighbors and most resembled *tet*(X)  
191 orthologs in the phylogeny designed *tet*(X15), *tet*(X15.2), *tet*(X15.3), *tet*(X16), *tet*(X16.2) and  
192 *tet*(X16.3) (Figure S1, Table S3). Most of these *tet*(X) orthologs found from metagenomic analysis  
193 were not present in the NCBI database with the exceptions of *tet*(X2) (Acc. No. AJ311171),  
194 *tet*(X2.4) (Acc. No. JQ990987) and *tet*(X16.2) (Acc. No. KU547718.1) (Table S3).

195 **Resistance phenotypes of *tet*(X) orthologs**

196 Both the *tet*(X15) and *tet*(X16) groups found from metagenomic analysis of human-gut origin  
197 (Figure 1c) in the *E. coli* JM109 were resistant to tigecycline (MICs 8 to 16 ml/liter), and  
198 exhibited high MIC to the fourth-generation antibiotics omadacycline (MICs 16 to 32 ml/liter) and  
199 eravacycline (MICs 2 to 4 ml/liter) (Table S4). In addition, all the non-*tet*(X2) exhibited resistance  
200 to tetracycline (MICs 128 to 256 ml/liter), doxycycline (MICs 32 to 64 ml/liter) and minocycline

201 (MICs 16 to 32 ml/liter) (Table S4). All the *tet*(X2) like orthologs were susceptible to tigecycline  
202 (MICs 0.25 to 1 ml/liter) but resistant to tetracycline (MICs 8 to 256/liter). Almost all of them  
203 were resistant to doxycycline (MICs 8 to 64 ml/liter) and minocycline (MICs 2 to 32 ml/liter),  
204 excluding *tet*(X2.10) that intermediate to doxycycline (1 ml/liter) and minocycline (MICs 0.5  
205 ml/liter). Most of these *tet*(X2) like orthologs exhibited MIC of omadacycline from 0.5 to 4  
206 ml/liter, and eravacycline from 0.0125 to 1 ml/liter (Table S4). Three *tet*(X2) like orthologs  
207 *tet*(X2), *tet*(X2.4) and *tet*(X2.15) showed relatively higher MICs to omadacycline (8 to 16 ml/liter)  
208 and eravacycline (1 to 4 ml/liter).

209 **Global distribution and taxonomic assignment of *tet*(X) carrying MGBs**

210 The 322 *tet*(X)s carrying MGBs were detected in 19 countries including Europe (n=12), Asia  
211 (n=4) and America (n=3) but were absent in Oceanica and Africa (Figure 1a, Table S5). The  
212 prevalence of *tet*(X) in European countries (0 - 9.40 %) was more complex than Asian (0 - 3.17 %)  
213 and American countries (0 - 2.44 %) although the positive rates for *tet*(X) in these three continents  
214 were not significantly (P>0.05) different (Figure S3). The prevalence of *tet*(X) was highest in  
215 Spain (9.40 %), followed by Germany (5.14 %), France (3.82 %), Denmark (3.34 %) and China  
216 (3.17 %) and the remaining countries were < 3 % (Figure 1a and Table S5).

217 The bacterial taxonomy assignment indicated that all the 322 *tet*(X)-carrying MGB could be  
218 assigned to five phyla and was dominated by *Bacteroidetes* (78.89 %, 254/322) followed by  
219 *Firmicutes* (16.78 %, 47/322), *Proteobacteria* (1.24 %, 4/322), *Candidatus Melainabacteria*  
220 (1.24%, 4/322) and *Fusobacteria* (0.62%, 2/322) (Figure 1b). Furthermore, 96.68% (301/322)  
221 were classified to the family level and most of them were also belonging to *Bacteroidaceae*  
222 (70.10%, 211/301) (Figure 1b and Table S6). Furthermore, 72.30% (154/211) of these *tet*(X)

223 carrying *Bacteroidaceae* MGBs could be further divided into 14 *Bacteroides* species that were  
224 dominated by *Bacteroides vulgatus* (37.67 %, 58/154), *Bacteroides uniformis* (20.78 %, 32/154),  
225 *Bacteroides dorei* (14.94 %, 23/154), *Bacteroides ovatus* (5.84 %, 9/154), *Bacteroides fragilis*  
226 (3.90 %, 6/154) and *Bacteroides caccae* (3.25 %, 5/154) (Table S7).

227 The *tet*(X2)-like positive MGBs were distributed across these 19 *tet*(X) positive countries.  
228 *tet*(X2.4) (55.02 %, 170/309), *tet*(X2) (26.86 %, 83/309), *tet*(X2.5) (9.32 %, 30/309) and *tet*(X2.2)  
229 (4.53 %, 14/309) totaled 96.11 % (297/309) and prevailed over other *tet*(X2)-like orthologs ( $\leq$   
230 0.6 %, 2/309) (Figure S4). Only 81.08% (240/296) of these four predominant *tet*(X) carrying  
231 MGBs could be assigned at genus level and most of them were also identified in *Bacteroides*  
232 (71.67%, 172/240), followed by *Prevotella* (6.67%, 16/240) and *Alistipes* (5%, 12/240) (Table S8).  
233 Additionally, the non-*tet*(X2) orthologs included 75 % (9/12) that were distributed in China and  
234 USA. Of which, *tet*(X15.2) was the most prevalent ortholog (Figure 1c). The remaining three  
235 non-*tet*(X2) carrying MGBs were distributed in Europe and the single *tet*(X16.2) ortholog was  
236 carried by an *Enterococcaceae* from Italy. Almost all *tet*(X)-carrying MGBs were collected from  
237 human stools excluding only one *tet*(X2.4)-carrying MGB identified as an *Enterococcus* spp. from  
238 an oral cavity sample (Table S8).

239 The 322 *tet*(X) carrying MGBs included 196 from the 4,390 MGBs and their average  
240 abundance in human microbiomes has been calculated in previous study (Table S8) (20). The  
241 average abundance of these 196 *tet*(X)-positive MGBs was  $5.97 \pm 3.89$  and significantly higher  
242 than that of the total 4,390 MGBs ( $1.76 \pm 3.74$ ) (20).

243 **Culturable isolates from public repository insight into the distribution and evolutionary**  
244 **timescale of Tet(X)s**

245 To further trace the distribution of these *tet*(X)s in culturable isolates, we examined 774,435  
246 WGS of bacterial isolates present in GenBank and only 0.12 % (896/774,435) carried an ORF  
247 with > 70 % amino acid identity with the known *tet*(X) genes including the novel ones found in  
248 the current study (Table S9). The PhyloPhlAn analysis indicated that the facultative anaerobe  
249 clade was phylogenetically distinct between anaerobes and aerobes (Figure 2a). These *tet*(X)  
250 genes were found in 17 bacterial families that were dominated by aerobes including  
251 *Moraxellaceae* (279/896, 31.17 %), *Enterobacteriaceae* (208/896, 23.24 %) and *Weeksellaceae*  
252 (16.20 %, 145/896). The *Bacteroidaceae* (20.67 %, 185/896) were also an important anaerobic  
253 carrier for *tet*(X2) like orthologs (Figure 2a and Table S9). Three *tet*(X) orthologs were most  
254 prevalent and included *tet*(X2)-like (35.71 %, 320/896), *tet*(X3) (27.34 %, 245/896) and *tet*(X4)  
255 (21.99 %, 199/896) (Table S9). Interestingly, different bacterial families from variant hosts were  
256 preference for carrying specific *tet*(X) ortholog (Figure 2a). Almost all the *Bacteroidaceae*  
257 (98.91 %, 182/184) and most *Weeksellaceae* (63.45 %, 92/145) isolates carried *tet*(X2)-like  
258 orthologs and were primarily from human samples (38.64 %, 114/295). Additionally, all *tet*(X3)  
259 were detected from *Acinetobacter* spp. and almost all *tet*(X4) (88.89 %, 176/197) were carried by  
260 *E. coli* and these were primarily from food animals (66.59 %, 295/443) including pigs, chickens,  
261 ducks, cattle and geese.

262 The *tet*(X2)-like orthologs were detected prior to  $8.41 \pm 6.17$  years ago and earlier than  
263 *tet*(X3) ( $4.00 \pm 1.12$ ) and *tet*(X4) ( $2.38 \pm 1.34$ ). To be noted, the collection dates of three *R.*  
264 *anatipestifer* isolates from UK duck samples were prior to 1980. One isolate (BioSample:  
265 SAMN09912225) was collected in 1966 and was positive for *tet*(X12) and a *tet*(X2)-like gene that  
266 only differed in a single amino acid from *tet*(X2) was designed *tet*(X2.17). The two other isolates

267 were collected in 1976. One (BioSample: SAMN09912224) carried a *tet*(X2.17) gene and another  
268 (BioSample: SAMN09912221) carried a *tet*(X) gene shared 98.20% similarity with *tet*(X16),  
269 designed *tet*(X16.4).

270 Date for lineage divergence of the earliest occurred *tet*(X) orthologs were produced by  
271 Bayesian phylogenetic inference (Figure 2b). The analysis indicated a mean rate of 0.28 SNP per  
272 year for these *tet*(X) during 1966-2018. The most-recent common ancestor (MRCA) of all *tet*(X)  
273 from this study was approximately from 1939 to 1965, and the tracer analysis revealed the  
274 presence of *tet*(X) most likely occurred in AD 1953 (95% highest posterior distributor (HPD) AD).  
275 Two main lineages that originated from *tet*(X2.17) and *tet*(X12), respectively, were observed in  
276 this phylogeny and both *tet*(X) orthologs were collected from the *Riemerella anatipesfifer* of duck  
277 origin from the UK in 1966 year.

## 278 **Annotation and comparison of the *tet*(X) genomic environment**

279 A total of 1218 *tet*(X)-carrying contigs ranging from 1,190 to 931,600 bp were retrieved from  
280 the metagenome and bacterial-isolate data. These contigs were grouped into 455 clusters that  
281 carried a range of 1 - 48 contigs (Table S10). In each cluster, longer contig shared more than 97%  
282 coverage and more than 97% similarity with shorter contig. The high coverage and similarity of  
283 these contigs indicated that these *tet*(X) could spread among each cluster (Table 10). This  
284 indicated *tet*(X) orthologs could spread among a great diversity of host including human, animal  
285 and environment (Figure 3). Both humans and pigs were the primary *tet*(X) hosts. *tet*(X2)-like  
286 *tet*(X3), *tet*(X4), *tet*(X7) and *tet*(X16.3) have been found in humans as well as *tet*(X2)-like, *tet*(X3),  
287 *tet*(X4) and *tet*(X6) in pigs. However, only *tet*(X2)-like and *tet*(X3) orthologs could transfer  
288 between these two hosts (Figure 3a). Interestingly, *tet*(X2)-like orthologs could hitch a great

289 diversity of vehicles to spread between humans and pigs and these included *Bacteroides* spp., *R.*  
290 *anatipesfier* and *Chryseobacterium* spp.. The remaining *tet*(X) genes were spread only *via* special  
291 species between different hosts. For instance, the *tet*(X3) gene could only be transited by  
292 *Acinetobacter* spp. and spread between pigs and other hosts including pigeons, cattle, geese, ducks  
293 and humans (Figure 3a). Additionally, the *tet*(X4) in the genomic array *rdmC-tet*(X4)- $\Delta$ *ISCR2*  
294 could spread among wild birds, humans, pigs, chickens and the environment (Figure 3b).

295 Genomic annotation and comparisons indicated that other ARGs frequently flanked the *tet*(X)  
296 gene and these included *ermF*, *aadK*, *tet*(Q) and *bla*<sub>OXA347</sub> that conferred resistance to erythrocin,  
297 streptomycin, tetracycline and ampicillin, respectively (Figure 4a and 4b). Of which, the *erm*(F)  
298 gene was the most frequently flanking the *tet*(X) gene (n=152) and their genomic environment  
299 were clustered into two types according to their relative position: *ermF* located upstream (15.79 %,  
300 24/152) and downstream (80.92 %, 123/152) of *tet*(X) gene (Figure 4a and 4b). The upstream  
301 *ermF* always formed a conserved structure *tnpF-ermF-tet*(X1)-*tet*(X2)/*tet*(X2.2)-*aadK* (n=24)  
302 (Figure 4a). This structure was also present in a conjugative transposon CTnDOT of *Bacteroides*  
303 origin (40), but the *aadK* (930 bp) was replaced by another aminoglycoside ARG *aadS* (903 bp) in  
304 CTnDOT and these two ARGs shared a 96.77 % identity at the nucleotide level. Interestingly, the  
305 *tet*(X) orthologs and their genomic contexts were more diverse when *ermF* was located  
306 immediately downstream of *tet*(X). These *tet*(X) genes included 12 orthologs that were dominated  
307 by *tet*(X2.4) and *tet*(X2.5) (Figure 4b, S1 text A1). In addition, these *tet*(X) genes were able to  
308 spread among anaerobes, aerobes and facultative anaerobes (text S1).

309 **Discussion and conclusion**

310 **Source tracking of the *tet*(X) orthologs**

311 One of the most significant findings in current study was that *tet(X)* emerged as early as  
312 1960s in *R. anatipesfifer* of duck origin, which was earlier than that had been previously reported  
313 in 1980s (8) but we found *tet(X)* was present. A previous epidemiological study indicated the  
314 MRCA of these *tet(X)*s orthologs likely occurred 9900 years ago (7887 BC) (15). However, we  
315 also estimated the MRCA of these *tet(X)* genes but determined it occurred only 68 years ago  
316 (1953 AD) that was only one year following the introduction of tetracycline in clinics. This was  
317 consistent with the streptomycin, erythrocin and florfenicol, in which their resistance also emerged  
318 over the ensuing years following their introduction in clinic [4]. In this analysis, we screened for  
319 the presence of *tet(X)* orthologs from public repositories on a large scale (774,435 isolates) and  
320 the earliest emergence of 28 *tet(X)* variants was selected to perform MRCA estimations (Figure  
321 2b). The time of the earliest occurrences of *tet(X)* were an important factor for the chronogram  
322 phylogeny construction using the Bayesian evolutionary analysis. Thus, these data should be  
323 validated to confirm these results.

324 The *Flavobacteriaceae* have been recognized as a potential ancestral source of the  
325 tigecycline resistance gene *tet(X)* (5). We found that both the two earliest (1966) occurring *tet(X)*  
326 orthologs (*tet(X2.17)* and *tet(X12)*) harbored by *R. anatipesfifer* that is also a bacterial species  
327 member belonging to *Flavobacteriaceae* family. Meanwhile, before 2000 only a total of seven  
328 isolates were confirmed as *tet(X)* gene carrier and five of them were also identified as *R.*  
329 *anatipesfifer* (Table S9). Among the 896 *tet(X)*-carrying isolates from public repository, 71  
330 *tet(X)*-carrying were *Flavobacteriaceae* including *R. anatipesfifer* that accounted for a large  
331 number (64.79%, 46/71) versus all other *Flavobacteriaceae* members (Figure 2a). Additionally, *R.*  
332 *anatipesfifer* harbored a great diversity of *tet(X)* variants and only 23.94 % (17/71) carried the

333 known *tet*(X)s including *tet*(X12), *tet*(X14), *tet*(X2.17) and *tet*(X16.4) (Figure 2a). The remaining  
334 carried other *tet*(X) orthologs that shared 94.9 - 99.7 % similarity with their most closely related  
335 *tet*(X) ortholog (Table S9). A recent study indicated the poultry pathogen *R. anatipesfifer* appears  
336 to be a reservoir for Tet(X) tigecycline resistance (41). These indicated that *R. anatipesfifer* was  
337 most likely the ancestral source of the tigecycline resistance gene *tet*(X).

338 A great diversity for *tet*(X) and their flanking genomic contexts was observed when the *ermF*  
339 gene was present downstream of *tet*(X) (Figure 4b and text S1). A comparison of the *tet*(X)  
340 genomic contexts from MGBs and culturable isolates yielded 11 genomic backbones that were  
341 associated with the formation of non-*tet*(X2) orthologs found in the current study (Figure 4b). The  
342 non-*tet*(X2) orthologs were likely to be generated from *tet*(X2)-like orthologs during their  
343 transmission between anaerobes or between anaerobes and facultative anaerobes (Figure 4b and  
344 text S1). *ISBf11* and *IS4351* played important roles in their transmission between anaerobes that  
345 was dominated by *Bacteroides* spp. where a mobile cyclic structure was speculated based on  
346 genomic Types I - IV (Figure 4b and text S1), and the *tet*(X15)-like and *tet*(X16)-like genes were  
347 likely to be generated during the transmission of this mobile structure. In addition, a  
348 self-transmissible cyclic structure lacking IS elements was also hypothesized based on the  
349 genomic Types V - XI. This structure likely transferred between *Bacteroides* spp. and *R.*  
350 *anatipesfifer* and *tet*(X16.4) was most likely generated during the transmission. In addition,  
351 genomic comparisons indicated that these *tet*(X) genes were also able to spread between  
352 *Flavobacteriaceae* and *E. coli* as well as between *Flavobacteriaceae* and *Acinetobacter* sp.  
353 (Figure 4c and text S1). We have demonstrated that *R. anatipesfifer*, a *Flavobacteriaceae* family  
354 member, was a potential ancestral source of *tet*(X) and the new *tet*(X) orthologs were likely to be

355 produced during their transmission. The high similarity of the nucleotide sequences flanking  
356 *tet*(X3) and *tet*(X4) (Figure 4c and text S1) suggested that these two genes were also derived from  
357 *Flavobacteriaceae* and *ISCR2* played a key role in this process (Figure 4c and text S1).

358 **Global distribution of *tet*(X) orthologs**

359 The human microbiome plays an important role in public health. Here, we first determine the  
360 *tet*(X) prevalence in the human microbiome using a large-scale survey of 12,829 samples (20-22).  
361 A total of 16 *tet*(X2)-like and two new non-*tet*(X2) orthologs have been identified directly in the  
362 human stool samples. Since there was not standard for assignment of the new found *tet*(X)  
363 orthologs, and it was necessary to distinguish the different *tet*(X) orthologs in current study. Thus,  
364 we temporarily set up a criterion for the assignment of *tet*(X) orthologs. This maybe not  
365 comprehensive as the assignment for mobile colistin resistance (*mcr*) genes (42) which have  
366 established a platform in NCBI (pd-help@ncbi.nlm.nih.gov) to confirm and allocate the allele  
367 numbers for new *mcr* gene. An allele numbers assignment for *tet*(X)s should be established  
368 urgently.

369 We found a prevalence for *tet*(X) at 1.21 % (322/26,548) that was higher than for *E. coli* and  
370 *K. pneumoniae* from hospital isolates (0.32%, 4/1520) (5) indicating that traditional culture  
371 methods have underestimated the prevalence of *tet*(X). Our results were similar to an  
372 epidemiological study that detected the *bla*<sub>NDM</sub> and *mcr-1* genes directly from samples that was  
373 higher than for the *E. coli* isolates (43).

374 The *tet*(X2)-like genes carrier in human microbiomes were dominated by the *Bacteroidaceae*  
375 in contrast to previous epidemiological studies where *tet*(X3) and *tet*(X4) were primarily carried  
376 by *A. baumannii* and *E. coli*, respectively (2, 15). The *Bacteroides* are predominant anaerobes

377 estimated to account for 25 - 30% of human gut microflora (44) while the *Enterobacteriaceae*  
378 normally constitutes only 0.1 - 1 % (45). We also found that the average abundance of  
379 *tet*(X)-carrying MGBs ( $5.97 \pm 3.89$ ) annotated as *Bacteroidaceae* prevailed over species-level  
380 genome bins ( $1.76 \pm 3.74$ ) in the human microbiome. This was likely the reason for the absence of  
381 *tet*(X3) and *tet*(X4) in our human microbiome analyses. Although *tet*(X) genes are inactive in  
382 anaerobes, the high abundance of *tet*(X2)-carrying MGBs and a variety of non-*tet*(X2)-like  
383 orthologs found in the current study indicated that the *Bacteroidaceae* were an important reservoir  
384 and mutational incubator for the mobile *tet*(X) orthologs in the human microbiome (Figure 5).  
385 Furthermore, the *Bacteroidaceae* could generate new non-*tet*(X2) orthologs with tigecycline  
386 inactivation functions, and the comparison of the *tet*(X) genomic environment suggested that these  
387 non-*tet*(X2) enabled transfer to facultative anaerobes and aerobes (Figure 5).

388 We have demonstrated *R. anatipesfifer* as potential ancestral source of *tet*(X) genes, and the  
389 earliest emergence of high-level tigecycline resistance genes *tet*(X3) and *tet*(X4) were likely to be  
390 1971 and 1982, respectively, both of which were earlier than the clinical introduction of  
391 tigecycline in 2005. This was further evidence that the use of even older antibiotic tetracycline  
392 may contribute to the resistance to newer antibiotics (4). The *tet*(X) distributions from culturable  
393 isolates indicated that *tet*(X2)-like and non-*tet*(X2) orthologs were prevalent in anaerobes and  
394 aerobes respectively (Figure 5). Since Tet(X) is active only in an aerobic environment, the  
395 non-*tet*(X2)-like orthologs with tigecycline inactivate function tended to be captured by aerobes  
396 under tetracycline selective pressure (Figure 5). This was likely to be the reason that non *tet*(X2)  
397 orthologs primarily distributed in aerobes but the high prevalence of *tet*(X2)-like orthologs in  
398 *Bacteroidaceae* from human microbiome need to be further explored.

399 Taxonomic assignments for *tet*(X)-carrying MGBs were estimated using bioinformatic  
400 methods that may not be as precise as cultural methods but such an approach has proved feasible  
401 (20, 46). Another limitation of this approach was challenging to combine the chromosome with  
402 their respective plasmid sequences (47). Therefore, these *tet*(X)-carrying contexts from MGBs in  
403 the current study were likely to be chromosome-borne. This differed with *tet*(X3)/*tet*(X4) that are  
404 present in a variety of plasmids and ISCR2 was an essential element for their mobilization (2, 15).  
405 Transmission between *Bacteroidaceae* of these *tet*(X)s orthologs was primarily mediated by the  
406 CTnDOT-like conjugative transposon and *ermF*-related IS elements including ISBf11 and IS4351.  
407 CTnDOT has been reported to harbor *ermF*, *tet*(X1) and *tet*(X2) in *Bacteroides* (40) and  
408 conjugative transposons can also insert into co-resident plasmids in addition to the chromosome  
409 (48). Therefore, conjugative transposons have been found in numerous genera including  
410 *Enterococcus*, *Streptococcus*., *Lactococcus*, *Butyrivibrio*, *Clostridium*, *Salmonella*, *Pseudomonas*,  
411 *Mezorhizobium* and *Vibrio* (40). The erythromycin resistance *ermF* gene is frequently reported in  
412 *R. anatipestifer* and *Bacteroides* spp. isolates (49, 50). The IS Bf11 and IS4351 flanking *tet*(X) in  
413 the Type III genomic contexts have also been previously identified (51) and reveals that this  
414 mobile structure has spread to China, the USA, France, Denmark, Sweden and Belgium. In  
415 addition, the ISCR2 element belonging to the IS91 family has been described in the first report of  
416 *tet*(X3) and *tet*(X4), both downstream and upstream of *tet*(X3). This IS element could form a  
417 mobile amplicon and this was demonstrated using inverse PCR experiments (7) and in an  
418 *Acinetobacter towneri* isolate flanking region of *tet*(X6) (52). We also identified this IS element  
419 located upstream of *tet*(X6) and indicated that this IS element can play an important role in  
420 transmission of non-*tet*(X2) orthologs with tigecycline inactivation functions in the

421 *Flavobacteriaceae*, *E. coli* and *Acinetobacter*.

422 In conclusion, we conducted an analysis integrated human gut metagenome and global  
423 bacterial isolates to trace the origin and distribution of *tet(X)* gene. The *tet(X)* gene emerged as  
424 early as 1960 and the *R. anatipestifer* was an ancestral source of *tet(X)*. The *tet(X3)*-carrying  
425 *Acinetobacter* spp. and *tet(X4)*-carrying *E. coli* were prevalent in food animals and these two  
426 *tet(X)*s were likely formed during the transmission of *tet(X)*s between *Flavobacteriaceae* and *E.*  
427 *coli/Acinetobacter*. The ISCR2 element played a key role in the transmission. The *tet(X2)*-like  
428 orthologs enriched in the anaerobes that was dominated by *Bacteroidaceae* of human-gut origin  
429 and could transfer between these anaerobes. The mobile elements CTnDOT, ISBf11 and IS4351  
430 played important roles in the transmission. The low-level tigecycline resistance *tet(X2)*-like gene  
431 could mutate to high-level tigecycline resistant determinants that could spread to facultative  
432 anaerobes and aerobes. *Bacteroidaceae* present in the human gut were an important reservoir and  
433 mutational incubator for *tet(X)* genes.

434

435 Acknowledgments

436 This work was supported by the National Natural Science Foundation of China (31730097), the  
437 Program for Changjiang Scholars and Innovative Research Team in University of Ministry of  
438 Education of China IRT\_17R39, the Local Innovative and Research Teams Project of Guangdong  
439 Pearl River Talents Program (2019BT02N054), and the 111 Project (D20008).

440 The authors are grateful to the previous studies that provide a large-scale of microbial genomic  
441 bins for the construction of the metagenomic analysis in current study.

442

443

444 **Reference**

- 445 1. Nelson ML, Levy SB. 2011. The history of the tetracyclines. *Ann N Y Acad Sci* 1241:17-32.
- 446 2. Fang LX, Chen C, Cui CY, Li XP, Zhang Y, Liao XP, Sun J, Liu YH. 2020. Emerging  
447 High-Level Tigecycline Resistance: Novel Tetracycline Destructases Spread via the Mobile  
448 Tet(X). *Bioessays* 42(8):e2000014.
- 449 3. Sarmah AK, Meyer MT, Boxall AB. 2006. A global perspective on the use, sales, exposure  
450 pathways, occurrence, fate and effects of veterinary antibiotics (VAs) in the environment.  
451 *Chemosphere* 65:725-59.
- 452 4. Aminov RI. 2013. Evolution in action: dissemination of *tet*(X) into pathogenic microbiota.  
453 *Front Microbiol* 4:192.
- 454 5. Zhang R, Dong N, Shen Z, Zeng Y, Lu J, Liu C, Zhou H, Hu Y, Sun Q, Cheng Q, Shu L, Cai J,  
455 Chan EW, Chen G, Chen S. 2020. Epidemiological and phylogenetic analysis reveals  
456 *Flavobacteriaceae* as potential ancestral source of tigecycline resistance gene *tet*(X). *Nat*  
457 *Commun* 11:4648.
- 458 6. Bertrand X, Dowzicky MJ. 2012. Antimicrobial susceptibility among gram-negative isolates  
459 collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin  
460 America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline  
461 Evaluation and Surveillance Trial. *Clin Ther* 34:124-37.
- 462 7. He T, Wang R, Liu D, Walsh TR, Zhang R, Lv Y, Ke Y, Ji Q, Wei R, Liu Z, Shen Y, Wang G,  
463 Sun L, Lei L, Lv Z, Li Y, Pang M, Wang L, Sun Q, Fu Y, Song H, Hao Y, Shen Z, Wang S,  
464 Chen G, Wu C, Shen J, Wang Y. 2019. Emergence of plasmid-mediated high-level tigecycline  
465 resistance genes in animals and humans. *Nat Microbiol* 4(9):1450-1456.
- 466 8. Guiney DG, Jr., Hasegawa P, Davis CE. 1984. Expression in *Escherichia coli* of cryptic  
467 tetracycline resistance genes from *bacteroides* R plasmids. *Plasmid* 11:248-52.
- 468 9. Yang W, Moore IF, Koteva KP, Bareich DC, Hughes DW, Wright GD. 2004. TetX is a  
469 flavin-dependent monooxygenase conferring resistance to tetracycline antibiotics. *J Biol*  
470 *Chem* 279:52346-52352.
- 471 10. Sun J, Yang RS, Zhang Q, Feng Y, Fang LX, Xia J, Li L, Lv XY, Duan JH, Liao XP, Liu YH.  
472 2016. Co-transfer of *bla*<sub>NDM-5</sub> and *mcr-1* by an IncX3-X4 hybrid plasmid in *Escherichia coli*.  
473 *Nat Microbiol* 1:16176.
- 474 11. Cheng Y, Chen Y, Liu Y, Guo Y, Zhou Y, Xiao T, Zhang S, Xu H, Chen Y, Shan T, Xiao Y,  
475 Zhou K. 2020. Identification of novel tetracycline resistance gene *tet*(X14) and its  
476 co-occurrence with *tet*(X2) in a tigecycline-resistant and colistin-resistant *Empedobacter*  
477 *stercoris*. *Emerg Microbes Infect* 9(1):1843-1852.
- 478 12. Wang L, Liu D, Lv Y, Cui L, Li Y, Li T, Song H, Hao Y, Shen J, Wang Y, Walsh TR. 2019.  
479 Novel plasmid-mediated *tet*(X5) gene conferring resistance to tigecycline, eravacycline and  
480 omadacycline in clinical *Acinetobacter baumannii*. *Antimicrob Agents Chemother*  
481 64(1):e01326-19.
- 482 13. Liu D, Zhai W, Song H, Fu Y, Schwarz S, He T, Bai L, Wang Y, Walsh TR, Shen J. 2020.  
483 Identification of the novel tigecycline resistance gene *tet*(X6) and its variants in *Myroides*,  
484 *Acinetobacter* and *Proteus* of food animal origin. *J Antimicrob Chemother* 75(6):1428-1431.

485 14. Gasparrini AJ, Markley JL, Kumar H, Wang B, Fang L, Irum S, Symister CT, Wallace M,  
486 Burnham CD, Andleeb S, Tolia NH, Wencewicz TA, Dantas G. 2020.  
487 Tetracycline-inactivating enzymes from environmental, human commensal, and pathogenic  
488 bacteria cause broad-spectrum tetracycline resistance. *Commun Biol* 3:241.

489 15. Chen C, Cui C-Y, Yu J-J, He Q, Wu X-T, He Y-Z, Cui Z-H, Li C, Jia Q-L, Shen X-G, Sun R-Y,  
490 Wang X-R, Wang M-G, Tang T, Zhang Y, Liao X-P, Kreiswirth BN, Zhou S-D, Huang B, Du  
491 H, Sun J, Chen L, Liu Y-H. 2020. Genetic diversity and characteristics of high-level  
492 tigecycline resistance *Tet(X)* in *Acinetobacter* species. *Genome Medicine* 12:111.

493 16. Li R, Lu X, Peng K, Liu Z, Li Y, Liu Y, Xiao X, Wang Z. 2020. Deciphering the Structural  
494 Diversity and Classification of the Mobile Tigecycline Resistance Gene *tet(X)*-Bearing  
495 Plasmidome among *Bacteria*. *mSystems* 5(2):e00134-20.

496 17. Hu Y, Liu F, Lin IY, Gao GF, Zhu B. 2016. Dissemination of the *mcr-1* colistin resistance gene.  
497 *Lancet Infect Dis* 16:146-7.

498 18. Wang Y, Liu F, Zhu B, Gao GF. 2020. Metagenomic data screening reveals the distribution of  
499 mobilized resistance genes *tet(X)*, *mcr* and carbapenemase in animals and humans. *J Infect*  
500 80:121-142.

501 19. Zeng J, Pan Y, Yang J, Hou M, Zeng Z, Xiong WJEi. 2019. Metagenomic insights into the  
502 distribution of antibiotic resistome between the gut-associated environments and the pristine  
503 environments. *Environ Int* 126:346-354.

504 20. Pasolli E, Asnicar F, Manara S, Zolfo M, Karcher N, Armanini F, Beghini F, Manghi P, Tett A,  
505 Ghensi P, Collado MC, Rice BL, DuLong C, Morgan XC, Golden CD, Quince C,  
506 Huttenhower C, Segata N. 2019. Extensive Unexplored Human Microbiome Diversity  
507 Revealed by Over 150,000 Genomes from Metagenomes Spanning Age, Geography, and  
508 Lifestyle. *Cell* 176:649-662.e20.

509 21. Nayfach S, Shi ZJ, Seshadri R, Pollard KS, Kyrpides NC. 2019. New insights from  
510 uncultivated genomes of the global human gut microbiome. *Nature* 568:505-510.

511 22. Forster SC, Kumar N, Anonye BO, Almeida A, Viciani E, Stares MD, Dunn M, Mkandawire  
512 TT, Zhu A, Shao Y, Pike LJ, Louie T, Browne HP, Mitchell AL, Neville BA, Finn RD, Lawley  
513 TD. 2019. A human gut bacterial genome and culture collection for improved metagenomic  
514 analyses. *Nat Biotechnol* 37:186-192.

515 23. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. 2018. MEGA X: Molecular Evolutionary  
516 Genetics Analysis across Computing Platforms. *Mol Biol Evol* 35:1547-1549.

517 24. Robert X, Gouet P. 2014. Deciphering key features in protein structures with the new  
518 ENDscript server. *Nucleic Acids Res* 42:W320-4.

519 25. Sun J, Chen C, Cui CY, Zhang Y, Liu X, Cui ZH, Ma XY, Feng Y, Fang LX, Lian XL, Zhang  
520 RM, Tang YZ, Zhang KX, Liu HM, Zhuang ZH, Zhou SD, Lv JN, Du H, Huang B, Yu FY,  
521 Mathema B, Kreiswirth BN, Liao XP, Chen L, Liu YH. 2019. Plasmid-encoded *tet(X)* genes  
522 that confer high-level tigecycline resistance in *Escherichia coli*. *Nat Microbiol* 4:1457-1464.

523 26. Uritskiy GV, DiRuggiero J, Taylor J. 2018. MetaWRAP-a flexible pipeline for  
524 genome-resolved metagenomic data analysis. *Microbiome* 6:158.

525 27. Wood DE, Salzberg SLJGb. 2014. Kraken: ultrafast metagenomic sequence classification  
526 using exact alignments. *Genome Biol* 15:R46.

527 28. Asnicar F, Thomas AM, Beghini F, Mengoni C, Manara S, Manghi P, Zhu Q, Bolzan M,  
528 Cumbo F, May U, Sanders JG, Zolfo M, Kopylova E, Pasolli E, Knight R, Mirarab S,

529         Huttenhower C, Segata N. 2020. Precise phylogenetic analysis of microbial isolates and  
 530         genomes from metagenomes using PhyloPhlAn 3.0. *Nat Commun* 11:2500.

531         29. Katoh K, Standley DM. 2013. MAFFT multiple sequence alignment software version 7:  
 532         improvements in performance and usability. *Mol Biol Evol* 30:772-80.

533         30. Capella-Gutiérrez S, Silla-Martínez JM, Gabaldón T. 2009. trimAl: a tool for automated  
 534         alignment trimming in large-scale phylogenetic analyses. *Bioinformatics* 25:1972-3.

535         31. Stamatakis A. 2014. RAxML version 8: a tool for phylogenetic analysis and post-analysis of  
 536         large phylogenies. *Bioinformatics* 30:1312-3.

537         32. Asnicar F, Weingart G, Tickle TL, Huttenhower C, Segata N. 2015. Compact graphical  
 538         representation of phylogenetic data and metadata with GraPhlAn. *PeerJ* 3:e1029.

539         33. Drummond AJ, Rambaut A. 2007. BEAST: Bayesian evolutionary analysis by sampling trees.  
 540         *BMC Evol Biol* 7:214.

541         34. Rambaut A, Drummond AJ, Xie D, Baele G, Suchard MA. 2018. Posterior Summarization in  
 542         Bayesian Phylogenetics Using Tracer 1.7. *Syst Biol* 67:901-904.

543         35. Letunic I, Bork P. 2019. Interactive Tree Of Life (iTOL) v4: recent updates and new  
 544         developments. *Nucleic Acids Res* 47:W256-w259.

545         36. Fu L, Niu B, Zhu Z, Wu S, Li W. 2012. CD-HIT: accelerated for clustering the  
 546         next-generation sequencing data. *Bioinformatics* 28:3150-2.

547         37. Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 30:2068-9.

548         38. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, Philippon A, Allesoe RL,  
 549         Rebelo AR, Florensa AF, Fagelhauer L, Chakraborty T, Neumann B, Werner G, Bender JK,  
 550         Stingl K, Nguyen M, Coppens J, Xavier BB, Malhotra-Kumar S, Westh H, Pinholt M, Anjum  
 551         MF, Duggett NA, Kempf I, Nykäsenoja S, Olkkola S, Wieczorek K, Amaro A, Clemente L,  
 552         Mossong J, Losch S, Ragimbeau C, Lund O, Aarestrup FM. 2020. ResFinder 4.0 for  
 553         predictions of phenotypes from genotypes. *J Antimicrob Chemother* 75(12):3491-3500.

554         39. Siguier P, Perochon J, Lestrade L, Mahillon J, Chandler M. 2006. ISfinder: the reference  
 555         centre for bacterial insertion sequences. *Nucleic Acids Res* 34:D32-6.

556         40. Whittle G, Hund BD, Shoemaker NB, Salyers AA. 2001. Characterization of the  
 557         13-KilobaseermF Region of the *Bacteroides* Conjugative Transposon CTnDOT. *Appl Environ  
 558         Microbiol* 67:3488-3495.

559         41. Umar Z, Chen Q, Tang B, Xu Y, Wang J, Zhang H, Ji K, Jia X, Feng Y. 2021. The poultry  
 560         pathogen *Riheimerella anatipestifer* appears as a reservoir for Tet(X) tigecycline resistance.  
 561         *Environ Microbiol* doi:10.1111/1462-2920.15632.

562         42. Partridge SR, Di Pilato V, Doi Y, Feldgarden M, Haft DH, Klimke W, Kumar-Singh S, Liu JH,  
 563         Malhotra-Kumar S, Prasad A, Rossolini GM, Schwarz S, Shen J, Walsh T, Wang Y, Xavier BB.  
 564         2018. Proposal for assignment of allele numbers for mobile colistin resistance (*mcr*) genes. *J  
 565         Antimicrob Chemother* 73:2625-2630.

566         43. Wang Y, Zhang R, Li J, Wu Z, Yin W, Schwarz S, Tyrrell JM, Zheng Y, Wang S, Shen Z, Liu Z,  
 567         Liu J, Lei L, Li M, Zhang Q, Wu C, Zhang Q, Wu Y, Walsh TR, Shen J. 2017. Comprehensive  
 568         resistome analysis reveals the prevalence of NDM and MCR-1 in Chinese poultry production.  
 569         *Nat Microbiol* 2:16260.

570         44. Moore WE, Cato EP, Holdeman LV. 1978. Some current concepts in intestinal bacteriology.  
 571         *Am J Clin Nutr* 31:S33-42.

572         45. Consortium HMP. 2012. Structure, function and diversity of the healthy human microbiome.

573 Nature 486:207-14.

574 46. Zhang R-M, Liu X, Wang S-L, Fang L-X, Sun J, Liu Y-H, Liao X-P. 2020. Distribution  
575 patterns of antibiotic resistance genes and their bacterial hosts in pig farm wastewater  
576 treatment systems and soil fertilized with pig manure. Sci Total Environ 758:143654.

577 47. Sczyrba A, Hofmann P, Belmann P, Koslicki D, Janssen S, Dröge J, Gregor I, Majda S, Fiedler  
578 J, Dahms E, Bremges A, Fritz A, Garrido-Oter R, Jørgensen TS, Shapiro N, Blood PD,  
579 Gurevich A, Bai Y, Turaev D, DeMaere MZ, Chikhi R, Nagarajan N, Quince C, Meyer F,  
580 Balvočiūtė M, Hansen LH, Sørensen SJ, Chia BKH, Denis B, Froula JL, Wang Z, Egan R,  
581 Don Kang D, Cook JJ, Deltel C, Beckstette M, Lemaitre C, Peterlongo P, Rizk G, Lavenier D,  
582 Wu YW, Singer SW, Jain C, Strous M, Klingenberg H, Meinicke P, Barton MD, Lingner T,  
583 Lin HH, Liao YC, et al. 2017. Critical Assessment of Metagenome Interpretation-a benchmark  
584 of metagenomics software. Nat Methods 14:1063-1071.

585 48. Salyers AA, Shoemaker NB, Li LY. 1995. In the driver's seat: the *Bacteroides* conjugative  
586 transposons and the elements they mobilize. J Bacteriol 177:5727-31.

587 49. Xing L, Yu H, Qi J, Jiang P, Sun B, Cui J, Ou C, Chang W, Hu Q. 2015. *ErmF* and *ereD* are  
588 responsible for erythromycin resistance in *Riheimerella anatipesfier*. PLoS One 10:e0131078.

589 50. Johnsen BO, Handal N, Meisal R, Bjørnholt JV, Gaustad P, Leegaard TM. 2017. *erm* gene  
590 distribution among *Norwegian Bacteroides* isolates and evaluation of phenotypic tests to  
591 detect inducible clindamycin resistance in *Bacteroides* species. Anaerobe 47:226-232.

592 51. Pan Y, Awan F, Zhenbao M, Zhang X, Zeng J, Zeng Z, Xiong W. 2020. Preliminary view of  
593 the global distribution and spread of the *tet(X)* family of tigecycline resistance genes. J  
594 Antimicrob Chemother 75(10):2797-2803.

595 52. Cheng Y, Chen Y, Liu Y, Song J, Chen Y, Shan T, Xiao Y, Zhou K. 2021. Detection of a new  
596 *tet(X6)*-encoding plasmid in *Acinetobacter townieri*. J Glob Antimicrob Resist 25:132-136.

597

## 598 Figure legends

599 Figure 1. Global distribution of *tet(X)*s from human microbiome. A. World map showed the  
600 positive rates of *tet(X)* gene in 19 countries and the colored countries represented the positive  
601 rates of *tet(X)* according to the hot map (>0% - 9.40%) at the bottom. The gray countries indicated  
602 they were negative for *tet(X)* gene. The size of the pie charts represented the numbers of  
603 *tet(X)*-positive MGBs and the colors in the pie charts indicated the composition of *tet(X)* variants.  
604 B. PhyloPhlAn analysis of the *tet(X)* carrying MGBs. The taxonomic assignments of the  
605 *tet(X)*-carrying MGBs were depicted with colored circles in the phylogenetic tree. The *tet(X)*  
606 variants carried by the MGBs, as well as oxygen demand, gram stain, age category and the

607 countries of the *tet*(X)-carrying MGBs were showed in the five colored rings surrounding the  
608 phylogenetic tree. C. Distribution of the 12 MGBs carried non-*tet*(X2) genes with tigecycline  
609 inactivate function.

610

611 Figure 2. Culturable isolates insight into *tet*(X) distribution patterns. A. PhyloPhlAn analysis of  
612 the *tet*(X)-carrying isolates from the public repository. The species of the *tet*(X)-carrying isolates  
613 were depicted with colored circles in the phylogenetic tree. The information of the *tet*(X) carrying  
614 isolates including *tet*(X) variants, oxygen demand, host, collection date and country were showed  
615 in the six colored rings surrounding the phylogenetic tree. B. Dates of lineage divergence of the  
616 earliest *tet*(X) orthologs as determined using Bayesian phylogenetic inference. The *tet*(X) variants,  
617 countries, host and species of these isolates were shown at the right region.

618

619 Figure 3. Possible transmission routes of the *tet*(X) genes. The colored circles surrounding the  
620 hosts represented the *tet*(X) carrying bacterial families. The dotted lines represented the possible  
621 transmission routes of the *tet*(X) genes between different hosts.

622 Figure 4. Comparison of *tet*(X) genomic environment. A. The genomic comparison of *erm*(F) gene  
623 located upstream of *tet*(X2)-like genes. The proportions of the *tet*(X2) and *tet*(X2.2) located  
624 downstream *tet*(X1) were showed in the pie chart. B. The genomic comparison of *tet*(X) genes  
625 located downstream *erm*(F). The proportions of the *tet*(X) variants located downstream of *erm*(F)  
626 were showed in the pie chart. The possible mechanisms of non-*tet*(X2) formations were showed in  
627 the two circles plotted with dotted line. C. Genomic comparison of the regions flanking *tet*(X3)  
628 and *tet*(X4) among *Flavobacteriaceae*, *Acinetobacter* and *E. coli*. Arrows indicate the directions

629 of transcription of the genes, and different genes are shown in different colors. Regions of  $\geq 99.0\%$   
630 nucleotide sequence identity are shaded light grey. Regions of 77% - 91% nucleotide sequence  
631 identity are shaded dark grey. The  $\Delta$  symbol indicates a truncated gene. IS, insertion sequence. See  
632 Table S11 for genomic Type I - XVII definitions.

633 Figure 5. Potential origin and main transmission routes of the *tet(X)* genes.

634

635 Supplementary files

636 Text S1. Description of the comparison of *tet(X)* genomic-environment in Figure 4 and S5.

637 Figure S1. Phylogenetic analysis of the Tet(X) at amino acid level.

638 Figure S2. Comparative analysis of the Tet(X2)-like orthologs at the amino acid level.

639 Figure S3. Significance analysis of *tet(X2)* distributions in Europe, Asia and America.

640 Figure S4. Distribution of *tet(X2)*-like orthologs among different bacterial genus, countries and  
641 age groups from microbial genomic bins of human-gut origin.

642 Figure S5. Comparative analysis of the *tet(X2)* genomic context among *E. coli*, *R. anatipestifer*,  
643 *Phocaeicola vulgatus* and *Odoribacter laneus*. Arrows indicate the directions of transcription of  
644 the genes, and different genes are shown in different colors. Regions of  $\geq 99.0\%$  nucleotide  
645 sequence identity are shaded light grey. The  $\Delta$  symbol indicates a truncated gene. IS, insertion  
646 sequence. See Table S11 for genomic Type XVIII – XXII definitions.

647 Table S1. A total of 12,829 non-duplicate metagenomic samples that derived from previous studies  
648 (see PMID of Publication).

649 Table S2. A total of 202,265 MGBs that was constructed from the 12,829 non-duplicate  
650 metagenomic samples.

651 Table S3. The *tet*(X2)-like and non *tet*(X2) orthologs designed in current study.

652 Table S4. Minimum inhibitory concentration of the *tet*(X)s from metagenomic analysis. TET:  
653 tetracycline; DOX: doxycycline; MIN: minocycline; TIG: tigecycline; ERA: eravacycline; OMA:  
654 omadacycline.

655 Table S5. Positive rates of *tet*(X) gene in 31 countries.

656 Table S6. Positive rates of *tet*(X) carrying MGBs annotated at family level.

657 Table S7. Positive rates of *tet*(X) carrying MGBs annotated at species level.

658 Table S8. Detail information of the 322 *tet*(X) carrying MGBs.

659 Table S9. Detail information of the 896 *tet*(X) carrying bacterial isolates.

660 Table S10. Clusters of the 1218 *tet*(X) positive contigs from the MGBs and bacterial isolates.

661 Table S11. Detail information of the *tet*(X) genomic context types I to XXII.

Figure 1





Figure 2

(a)



(b)





Figure 3

Taxonomy of isolates  
at family level

- Moraxellaceae
- Enterobacteriaceae
- Bacteroidaceae
- Weeksellaceae
- Flavobacteriaceae
- Morganellaceae
- Tannerellaceae
- Prevotellaceae

(a)



(b)




Figure 4




Figure 5

